Download MendeleyStructure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Cogan, D.A., Aungst, R., Breinlinger, E.C., Fadra, T., Goldberg, D.R., Hao, M.H., Kroe, R., Moss, N., Pargellis, C., Qian, K.C., Swinamer, A.D.(2008) Bioorg Med Chem Lett 18: 3251-3255
- PubMed: 18462940
- DOI: https://doi.org/10.1016/j.bmcl.2008.04.043
- Primary Citation of Related Structures:
3CTQ - PubMed Abstract:
A computer-aided drug design strategy leads to the identification of a new class of p38 inhibitors based on the 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) scaffold. The tolyl triazole amides provided a potent platform amenable to optimization. Further exploration leads to compounds with greater than 100-fold improvement in binding affinity to p38. Derivatives prepared to alter the physicochemical properties produced inhibitors with IC(50)'s in human whole blood as low as 83 nM.
Organizational Affiliation:
Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc., Research and Development Center, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877, USA. derek.cogan@boehringer-ingelheim.com
